glypican 3 Polyclonal Antibody, Cy5.5 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-1112R-Cy5.5 |
| Product Name | glypican 3 Polyclonal Antibody, Cy5.5 Conjugated |
| Applications |
WB
FCM
|
| Reactivity | Human, Mouse |
| Predicted Reactivity | Rat |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human glypican 3 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 2719 |
| Subcellular location | Secreted, Cell membrane, Extracellular matrix |
| Synonyms | glypican 3; glypican3; glypican-3; GPC3; Intestinal protein OCI-5; GTR2-2; MXR7.Intestinal protein OCI-5. |
| Background | Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome. (Also known as glypican 3; Intestinal protein OCI-5; GTR2-2; MXR7; Glypican-3 precursor). |
| Application Dilution | |
| WB | 1:300-5000 |
| FCM | 1:20-100 |